## UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.	2630-127	ς <del>L</del>	
First Inventor	Markku ANTTILA	u.s 772	

(Only for new nonprovisional applications under 37 CFR 1.53(b))    Ittle   Method for Enhancing the Bioavailability of Ospemifene						
Applicant for Published Patent Applicati n: Hormos Medical Corporation FIN-20520 Turku, Finland						
APPLICATION ELEMENTS  See MPEP chapter 600 concerning utility patent application contents.			ADDRESS TO: Assistant Commissioner of Patents Box Patent Application Washington, D.C. 20231			
1.		or Compute  8. Nucleotide and a.	ent verifying identity in the control of the contro	uence Submission (CRF) on: oies); or of above copies ON PARTS et & document(s))  iif applicable) nt /PTO 1449  P 503) nent(s).		
17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below or in an application Data Sheet under 37 CFR 1.76::  Continuation Divisional Continuation-in-part (CIP) of prior application No.:  Prior application information: Examiner Group/Art Unit  For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.						
Customer Number or Bar Code Label 6449						
Address	Address Rothwell, Figg, Ernst & Manbeck Suite 800, 1425 K Street, N.W.					
City	Washington	State	D.C.	Zip Code	20005	
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031	
Name	Jeffrey L. Ihnen, Reg. No. 28,957					
Signature My Mh			Date 13 FEBRUARY 2004			